Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245713
Licensed Patent 8981089B2 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS. Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of metastatic HCC, an aggressive type of liver cancer.
IPSCIO Record ID: 243433
The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.
RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.
Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.
Licensee has capabilities in the development of oncology products.
IPSCIO Record ID: 283332
Licensee acquired all rights, including composition of matter patents (the â€œPKCd Patentsâ€), and preclinical study data to a novel therapeutic technology platform, known as protein kinase C delta (PKCd) inhibitors, which represents a unique, highly-targeted approach to treat cancer and to boost the immune system.
IPSCIO Record ID: 27879
IPSCIO Record ID: 266704
Licensed Compounds shall mean those certain Licensor compounds currently known as M_-4827 with the following chemical name 2 [4 (3S) 3 PIPERIDINYLPHENYL] 2H INDAZOLE 7 CARBOXAMIDE and M_-2512 with the following chemical name 6 (3 [(4 CYCLOPENTYL 3 OXYPIPERAZIN 1 XL)CARBONYL] 4 FLUOROBENZYL] 4,5 DIMETHYLPYRIDAZIN 3(21-l) ONE], and with respect to both, shall include any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof that but for the license granted, would infringe the Compound Patent Rights.
M_-4827, also known as Niraparib, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor in cancer patients as a monotherapy.
M_-2512 is the backup PARP inhibitor compound.